MET and breast carcinoma: The IHC biomarkers that were good predictors for survival (Figure 4) were the estrogen receptor (ER) (in ovarian surface epithelial carcinomas and breast carcinomas), progesterone receptor (PR) (in breast carcinomas, female genital tract malignancies, and ovarian surface epithelial carcinomas) and androgen receptor (AR) (in breast carcinoma), along with those for P-glycoprotein (PGP) (no specific cohort), tyrosine-protein kinase Met (cMET) (no specifc cohort) and the DNA excision repair protein ERCC1 (in NSCLC).